Globus Medical GMED
United StatesHealthcare · Medical DevicesUSD
100.92 USD (+36.8%)
13 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Globus Medical, Inc. is a medical device company that designs, develops, and markets products for spine and orthopedic surgery, including implants and surgical navigation systems.
Key points
from its scores- ✓Very solid balance sheet8.4
- ✓Good share-price trend8.4
- ✓High-quality business7.0
- ✕Little or no dividend1.5
- ✕Weak growth3.4
AI analysis
bottom line, main risk, context and newsFinancial strength and reasonable valuation (P/E 18.91) offset weakness in earnings growth, but without clear catalysts, upside potential is limited.
Globus Medical shows solid financial health (score 8.38) with net cash and an operating margin of 24.75%, but its earnings growth is negative (-26.20%) and it pays no dividend, which weighs on its growth profile and dividend yield.
The main risk is the slowdown in earnings growth (-26.20%), which could indicate demand issues or competitive pressure in the spine device market.
Context and risks
Globus Medical operates in the medical device sector, subject to ongoing regulatory scrutiny by the FDA and potential changes in Medicare reimbursement policies, which could affect demand for its products. Although the company has a solid financial position, the inherent regulatory uncertainty in the sector justifies a moderate risk adjustment.
Is Globus Medical stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 32% below the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 18.9 | 26.7 | −29% |
| EV / EBITDA | 9.3 | 14.5 | −36% |
| Price / book | 2.1 | 4.1 | −49% |
| Price / sales | 3.1 | 3.4 | −8% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 6.6 out of 10 (median for Healthcare: 4.7).
Average analyst target: 100.92 USD, +36.8% versus the price.
A discount may reflect more risk or slower growth than its sector: Financial health 8.4 (sector 6.5), Growth 3.4 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 18.9
- Forward P/E
- 13.7
- EV / EBITDA
- 9.3
- Price / book
- 2.1
- Price / sales
- 3.1
- PEG
- 1.49
- Market cap
- 9.9B USD
- Enterprise value
- 9.4B USD
Profitability
- ROE
- 11.8%
- ROA
- 8.7%
- ROIC (approx.)
- 15.9%
- Gross margin
- 69.0%
- Operating margin
- 24.8%
- Net margin
- 17.0%
- Free cash flow
- 554.2M USD
- FCF yield
- 5.6%
- Cash conversion
- 55%
Solvency
- Total debt
- 111.9M USD
- Net debt
- −483.2M USD
- Cash
- 595.1M USD
- EBITDA
- 1.0B USD
- Net debt / EBITDA
- −0.48
- Debt / equity
- 2.35
- Current ratio
- 4.62
- Quick ratio
- 2.78
Growth
- Revenue growth
- +5.9%
- Earnings growth
- −26.2%
- EPS (TTM)
- 3.90 USD
- EPS (forward)
- 5.40 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.96
- Analyst consensus
- Buy (13)
- Target price
- 100.92 USD
- 52-week range
- 56.50 – 101.40
Recent news
All GMED news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Globus Medical
Is Globus Medical stock cheap or expensive?
On P/E and EV / EBITDA, it trades 32% below the Healthcare median on average. Valuation score: 6.6 out of 10 (median for Healthcare: 4.7). Average analyst target: 100.92 USD, +36.8% versus the price. This is not investment advice.
What score does Globus Medical get on MeridIAn Screener?
It scores 6.2 out of 10, rank 807 of 2,130 (better than 60% of the companies analysed). Its strongest category is Financial health (8.4) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is Globus Medical's P/E ratio?
Its P/E is 18.9: the share price equals 18.9 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 13.7.
How much is Globus Medical worth on the stock market?
Its market capitalisation is 9.9B USD and its enterprise value, debt included, is 9.4B USD.
How much debt does Globus Medical have?
It has more cash than debt: net cash of 483.2M USD.
Does Globus Medical pay a dividend?
It pays no dividend, or almost none.
How has Globus Medical stock performed over the last year?
It has risen 30.4% over the last year, excluding dividends. Over the last 52 weeks it has traded between 56.50 and 101.40 USD. Past performance does not guarantee future results.
What do analysts think of Globus Medical?
13 analysts cover it; their average recommendation is “Buy” and their average target is 100.92 USD (+36.8% versus the price). It is an estimate, not market data.